Dyadic Announces Third Quarter 2024 Financial Results and Strategic Progress Across Key Markets
Dyadic International, Inc. (DYAI)
NASDAQ:AMEX Investor Relations:
dyadic.com
Company Research
Source: GlobeNewswire
Highlights Revenue Milestones and Expands Alternative Protein & Pharmaceutical Partnerships with Dapibus™ & C1 Technology Platforms Alternative Proteins Demonstrated substantial revenue increase for Q3 2024, driven primarily by Dapibus™ license fees and milestone payments.Received $1 million milestone payment for animal-free recombinant albumin products.Received $425,000 success fees for achieving production targets in a dairy enzyme collaboration.Expanded recombinant life science protein portfolio within six additional products in development for molecular biology and cell culture media applications. Human Health Co-developed a highly productive C1-produced ferritin nanoparticle Mpox (monkeypox) antigen with ViroVax LLC, achieving 4.5 g/L in 7 days; ViroVax is scheduled to begin preclinical studies for the Mpox vaccine beginning in Q4 2024.Further advanced our collaborations with two top ten pharmaceutical companies and a leading biotech company, having successfully expressed an a
Show less
Read more
Impact Snapshot
Event Time:
DYAI
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
DYAI alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
DYAI alerts
High impacting Dyadic International, Inc. news events
Weekly update
A roundup of the hottest topics
DYAI
News
- Dyadic Receives $3 Million Grant to Develop Cost-Effective Monoclonal Antibodies for RSV and Malaria Using C1 Platform Technology [Yahoo! Finance]Yahoo! Finance
- Dyadic Receives $3 Million Grant to Develop Cost-Effective Monoclonal Antibodies for RSV and Malaria Using C1 Platform TechnologyGlobeNewswire
- Dyadic International Third Quarter 2024 Earnings: Beats Expectations [Yahoo! Finance]Yahoo! Finance
- Dyadic International, Inc. (NASDAQ: DYAI) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $6.00 price target on the stock.MarketBeat
- Dyadic International Inc (DYAI) Q3 2024 Earnings Call Highlights: Revenue Surge and Strategic ... [Yahoo! Finance]Yahoo! Finance
DYAI
Earnings
- 11/12/24 - Beat
DYAI
Analyst Actions
- 11/14/24 - HC Wainwright
DYAI
Sec Filings
- 12/20/24 - Form 144
- 11/26/24 - Form 8-K
- 11/25/24 - Form 4
- DYAI's page on the SEC website